Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
RAPIVAB peramivir 200 mg / 20 mL concentrate for intravenous infusion glass vial, Biocelect Pty Ltd, CON-870
Product name
RAPIVAB peramivir 200 mg / 20 mL concentrate for intravenous infusion glass vial
Sponsor name
Biocelect Pty Ltd
Batches
C2000129
Consent start
Consent no.
CON-870
Standard
Paragraphs 8(1)(d), 8(1)(f), 8(1)(g), 8(1)(h), 9(1)(g) and 9(3)(a); and Subparagraphs 10(3)(a)(i) of Therapeutic Goods Order No. 91 '“ Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product does not conform with the requirements of Section 6 'main label';
Paragraphs 8(1)(d), 8(1)(f), 8(1)(g), 8(1)(h), 9(1)(g) and 9(3)(a); and
Subparagraphs 10(3)(a)(i) of TGO 91 in that the product packaging does not
comply with the following ' The carton label does not include the medicine name
more conspicuously on the main panel; does not include the approved name of the
dosage form 'Concentrated Injection'; does not indicate the location of the
batch and expiry prefixes; does not include the statement 'Protect from light';
does not include the words 'for infusion' adjacent to the name of the dosage
form; does not include the name and quantity of the active ingredient together
on one line immediately below the medicine name; and does not state the amount
of the excipient 'sodium chloride' in the volume of fill of the injection in the
container (i.e. 20 mL). ' The vial label does not include the approved name of
the dosage form 'Concentrated Injection'; does not indicate the location of the
batch and expiry prefixes; and does not include the statement 'Protect from
light'.
Conditions imposed
1. A 'Dear Healthcare Professional' letter identical to that provided in the
email correspondence to the Therapeutic Goods Administration dated 22
September 2021 will be supplied with each affected batch outlining the
non-compliance in the product labelling.
2. The labels to which this consent applies are those provided in the email
correspondence to the Therapeutic Goods Administration dated 22
September 2021
Therapeutic product type
Prescription medicines